Search Results for: covid-19
Articles
EXECUTIVE INTERVIEW - ICON: Transforming Clinical Trials in a Rapidly Shifting Landscape April 3, 2023
Ute Berger, MD, President, Development & Commercialization Solutions at ICON plc, discusses how with the acquisition of PRA in 2021, it has enhanced its value proposition and how it is transforming clinical trials in a rapidly shifting landscape.
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases April 3, 2023
HCW Biologics Inc. recently published a pivotal scientific paper in Aging Cell titled Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretary phenotype in mice with Dr. Hing C. Wong, the company’s Founder and CEO, as lead and….
WACKER, CordenPharma, LMU & HU Berlin Train Machine Learning Algorithm for the Formulation of RNA Actives March 31, 2023
Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), Wacker Chemie AG and CordenPharma...Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder March 28, 2023
Revive Therapeutics Ltd. recently provided an update on the company’s Phase 1/2 clinical study (NCT05322954) evaluating the safety and feasibility...Vaccitech Announces Positive Topline Final Data for HBV002 Study in People With Chronic Hepatitis B March 28, 2023
Vaccitech plc recently announced positive topline final data from the HBV002 study (NCT04778904), a Phase 1b/2a clinical trial of VTP-300...Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program March 23, 2023
Arch Biopartners Inc. recently announced it is receiving advisory services and up to $4 million in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the….
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia March 20, 2023
Vaxxinity, Inc. recently announced the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein….
Evonik Opens New Facility for Pharmaceutical Lipids at Site in Germany March 8, 2023
Evonik is opening a new GMP facility to manufacture lipids for advanced, pharmaceutical drug delivery applications. The lipid launch facility is located at the company’s site in Hanau, Germany and….
MARKET TRENDS - Emerging Trends in Injectable Drug Formulation & Delivery March 1, 2023
Martin Gonzalez, PhD, details current trends in sterile injectable formulations and delivery devices and highlights the challenges pharma and its CDMO partners are facing bringing emerging parenteral breakthroughs to patients.
SUSTAINABILITY - Is the Pharmaceutical Industry Preparing Effectively for a Greener Future? March 1, 2023
Michael Earl reviews 25 of the biggest pharma companies reporting environmental, social, and governance (ESG) scores to see how the industry is performing.
AUTOMATED SOLUTIONS - Automation & Shared Knowledge Pave the Way Into the Future March 1, 2023
Luca Valeggia says by no means is automation a novel concept for most research labs, but its swift advancement and expansion into new fields such as synthetic biology have shown us that we are only witnessing the start of what is possible.
CLINICAL TRIALS - New Technology & the Global COVID Pandemic Drive the Need for More Decentralized Trials March 1, 2023
Suhas Gudihal, MS, MBA, explains how the COVID-19 pandemic has accelerated the ongoing shift to remote clinical trial monitoring, and remote site access and monitoring platforms are now an essential element of the clinical trial process and a vital connection between the sponsor, CRO, and research site.
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial for Treatment of Moderate-to- Severe Vasomotor Symptoms Associated With Menopause February 13, 2023
Acer Therapeutics Inc. recently announced full enrollment of its Phase 2a proof of concept trial of ACER-801 (osanetant), a novel,...Vaxxas Initiates Phase 1 Clinical Study of First Needle-Free, Inactivated Seasonal Influenza Vaccine Quadrivalent Delivered Using High-Density Microarray Patch February 10, 2023
Vaxxas recently announced the initiation of a Phase 1 clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent...MARKET REPORT - Survey Suggests Global Innovation to Recover Much More Quickly Than Expected in 2023 February 9, 2023
After a brief fall in 2022 to a score of 6.5 – the first decline since its inception in 2018 – the index has surged to a record score of 7.4. This sudden recovery in scores over a little more than 8 months bodes extremely well for device and packaging manufacturers in the year ahead, suggesting a strong global recovery in industry outlook and confidence.
Revive Therapeutics Enters Research Collaboration Agreement With PharmaTher for Development of MDMA Transdermal Patch February 3, 2023
Revive Therapeutics Ltd. recently announced it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. to evaluate the delivery of 3,4-Methylenedioxymethamphetamine (MDMA) using PharmaTher’s novel microneedle….
Brand New State-of-the-Art Nemera Manufacturing Facility Inaugurated in Poland January 25, 2023
Based in Szczecin, this facility will significantly boost Nemera’s manufacturing capabilities and bring more drug delivery device solutions to patients…..
Alvotech & Bioventure Announce Approval of AVT02 (Adalimumab) as Simlandi in Saudi Arabia January 24, 2023
AVT02 as Simlandi is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure….
Needle-Free Patch Technology for mRNA Vaccines Aims to End Need for Frozen Storage & Improve Access January 17, 2023
CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas have recently signed a partnership agreement to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology in a project….
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis & Discloses Clinical Development Plan January 17, 2023
Kinarus Therapeutics AG recently announced preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral...
